Cabozantinib

Phase 1Recruiting

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Ewing Sarcoma

Conditions

Ewing Sarcoma, Osteosarcoma, Sarcomas

Trial Timeline

Oct 24, 2023 → Nov 1, 2028

NCT ID

NCT06156410

About Cabozantinib

Cabozantinib is a phase 1 stage product being developed by Exelixis for Ewing Sarcoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06156410. Target conditions include Ewing Sarcoma, Osteosarcoma, Sarcomas.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01683110	Pre-clinical	Completed	—	—	Medullary Thyroid Cancer
NCT06132945	Phase 1	Active	Nov 10, 2023	Nov 1, 2027	Metastatic Renal Cell Carcinoma
NCT06156410	Phase 1	Recruiting	Oct 24, 2023	Nov 1, 2028	Ewing Sarcoma
NCT05613894	Phase 1	Recruiting	Jul 14, 2023	May 1, 2028	Metastatic Castration-resistant Prostate Cancer
NCT05135975	Phase 2	Recruiting	Jul 20, 2022	Dec 1, 2029	Neuroblastoma
NCT05425004	Phase 2	Recruiting	Jun 1, 2022	May 1, 2028	Meningioma
NCT04497038	Phase 1/2	Terminated	Aug 6, 2021	May 2, 2023	Advanced Adult Hepatocellular Carcinoma
NCT04876456	Phase 2	Active	Jun 10, 2021	Jan 1, 2027	Germ Cell Tumor
NCT04631744	Phase 2	Completed	Mar 3, 2021	Nov 9, 2025	Prostate Cancer
NCT04412629	Phase 2	Active	Nov 24, 2020	Sep 30, 2026	High Grade Neuroendocrine Neoplasms
NCT03964337	Phase 2	Terminated	Mar 17, 2020	Jun 4, 2021	Prostate Cancer
NCT04022343	Phase 2	Active	Aug 6, 2019	Mar 1, 2026	Clear Cell Renal Cell Carcinoma
NCT02132598	Phase 2	Terminated	Dec 1, 2015	Aug 9, 2019	Non Small Cell Lung Cancer (NSCLC)
NCT02036476	Phase 2	Terminated	Feb 1, 2014	Jul 1, 2016	Merkel Cell Carcinoma
NCT01961765	Phase 1	Completed	Nov 1, 2013	Jan 1, 2017	Relapsed Acute Myeloid Leukemia
NCT01954745	Phase 2	Completed	Sep 1, 2013	Jun 1, 2016	Bile Duct Cancer
NCT01761773	Phase 1	Completed	Dec 1, 2012	Jul 1, 2014	Healthy
NCT01639508	Phase 2	Recruiting	Jul 1, 2012	Jul 1, 2026	Non-Small Cell Lung Cancer
NCT01428219	Phase 2	Terminated	Feb 1, 2012	Sep 1, 2015	Prostate Cancer Metastatic
NCT01493869	Phase 1	Completed	Sep 1, 2011	Aug 1, 2014	Healthy

Competing Products

14 competing products in Ewing Sarcoma

See all competitors

Product	Company	Stage	Hype Score
Linsitinib	Astellas Pharma	Phase 2	52
irinotecan liposome (II) + temozolomide + fluzoparib	Sun Pharmaceutical	Phase 2	52
Abemaciclib + Irinotecan + Temozolomide	Eli Lilly	Phase 2	52
IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab)	Eli Lilly	Phase 2	52
Xaluritamig	Amgen	Phase 1	32
CP-751,871	Pfizer	Phase 1	32
CP-751,871	Pfizer	Phase 1/2	40
Palbociclib + Temozolomide + Irinotecan + Topotecan + Cyclophosphamide	Pfizer	Phase 2	51
plerixafor + plerixafor + plerixafor	Sanofi	Phase 1/2	40
regorafenib tablet	Bayer	Phase 1	30
INCB059872	Incyte	Phase 1	30
Lurbinectedin	Jazz Pharmaceuticals	Phase 1/2	38
Lurbinectedin	Jazz Pharmaceuticals	Phase 1/2	38
INBRX-109 + Irinotecan + Temozolomide + carboplatin + pemetrexed + Leucovorin + Fluorouracil	Inhibrx Biosciences	Phase 1	28

Other Products from Exelixis

Cabozantinib (XL184) 140 mg + Cabozantinib (XL184) 60 mg + Placebo tablet + Placebo capsuleApproved

cabozantinib + prednisonePhase 3

Cabozantinib tablets + Everolimus (Afinitor) tabletsPhase 3

XL184 + PlaceboPhase 3

XL092 + Atezolizumab + RegorafenibPhase 3